For example, some compounded versions of GLP-1s include the investigational drug retatrutide, which is illegal for compounding and hasnt been FDA-approved
These findings underscore that GLP-1 therapy is a long-term intervention rather than a short-term solution
Beyond these primary endpoints, TRIUMPH-1 includes a range of secondary and exploratory endpoints that paint a fuller picture of retatrutide's clinical impact: Proportion of participants achieving 10%, 15%, and 20% or greater weight loss Changes in waist circumference Changes in cardiometabolic risk factors, including blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, and fasting glucose Changes in HbA1c (a measure of average blood sugar over the preceding two to three months) Changes in liver enzymes and markers of hepatic health Patient-reported outcomes related to quality of life and physical function Safety and tolerability, including the incidence and severity of adverse events The secondary endpoints are particularly important for retatrutide because the Phase 2 data showed striking improvements across metabolic markers
[DOI] [PMC free article] [PubMed] [Google Scholar] 98.Bakinowska E., Krompiewski M., Boboryko D., Kiebowski K., Pawlik A
GIP receptor activation enhances glucose disposal, whilst GLP-1 receptor activation provides glucose-dependent insulin secretion, creating optimal glycaemic control without excessive glucose production from glucagon receptor modulation
Most women at Josie say they notice this first, and theyre not obsessing over food anymore
